Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Medytox Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners across 2 distinct art units. MONSHIPOURI, MARYAM is the named busiest examiner, with 1 pending action.
The examiner spread makes coordinated prosecution important. Counsel should compare claim terminology and technical arguments across the matters, while allowing for different examination approaches within the two art-unit assignments.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONSHIPOURI, MARYAM | 1 | 79.2% | +37.2% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.2% | +38.9% |
| STIGELL, THEODORE J | 1 | 78.3% | +14.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709913 | BOTULINUM NEUROTOXIN COMPOSITION | MONSHIPOURI, MARYAM | 15d overdue |
| 17995428 | BOTULINUM TOXIN PRE-FILLED INJECTABLE FORMULATION THAT FACILITATES DISCHARGE RATE CONTROL AND IS STABLE | STIGELL, THEODORE J | 6d |
| 18574843 | RECOMBINANT BOTULINUM TOXIN TYPE A LIGHT CHAIN, RECOMBINANT BOTULINUM TOXIN, AND COMPOSITION, USE, AND METHOD THEREOF | PAGUIO FRISING, MICHELLE F | — |
| Art Unit | Apps |
|---|---|
| 1651 | 2 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709913 | BOTULINUM NEUROTOXIN COMPOSITION | MONSHIPOURI, MARYAM | 1651 | §112DP | Final Rejection | 15d overdue | Pending | May 14, 2024 |
| 18574843 | RECOMBINANT BOTULINUM TOXIN TYPE A LIGHT CHAIN, RECOMBINANT BOTULINUM TOXIN, AND COMPOSITION, USE, AND METHOD THEREOF | PAGUIO FRISING, MICHELLE F | 1651 | §102§112DP | Non-Final OA | — | Pending | Dec 28, 2023 |
| 17995428 | BOTULINUM TOXIN PRE-FILLED INJECTABLE FORMULATION THAT FACILITATES DISCHARGE RATE CONTROL AND IS STABLE | STIGELL, THEODORE J | 3783 | §103 | Non-Final OA | 6d | Pending | Oct 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedytox Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Maryam Monshipouri has the most, with 1 of Medytox Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
